Tag

Pfizer

All articles tagged with #pfizer

Most TrumpRx-listed drugs have cheaper generics, study finds
healthcare19 days ago

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

Pfizer's long-acting obesity shot shows promise with monthly dosing in mid-stage trial
business22 days ago

Pfizer's long-acting obesity shot shows promise with monthly dosing in mid-stage trial

Pfizer reported mid-stage results for PF′3944, an ultra-long-acting GLP-1 obesity drug, showing up to 12.3% weight loss vs placebo at week 28 and about 10.5% when including discontinuations, with no plateau after switching to monthly dosing—suggesting continued weight loss through week 64. The data imply monthly dosing could match weekly regimens, offering convenience in a market led by Eli Lilly and Novo Nordisk. Pfizer plans 10 phase 3 trials this year; modeling suggests a higher monthly dose could achieve roughly 16% weight loss at week 28. The drug was generally well tolerated with mostly mild to moderate GI side effects and some discontinuations due to side effects in both weekly and monthly phases.

Pfizer bets on Metsera and cost cuts as Q4 beats amid waning Covid sales
business23 days ago

Pfizer bets on Metsera and cost cuts as Q4 beats amid waning Covid sales

Pfizer beat Q4 estimates with adjusted EPS of 66 cents on $17.56 billion in revenue, despite weaker demand for its Covid vaccine and Paxlovid; it reaffirmed a modest 2026 outlook, plans about $7.7 billion in cost cuts by 2027, and is betting on long-term growth from the Metsera acquisition, including obesity therapy data, while facing ongoing price pressure in Medicaid and competitive pressures on older drugs.

Pfizer's Q4 Preview: Beat Likely, but Upside Hinges on Drug Updates and US Pricing Policy
business23 days ago

Pfizer's Q4 Preview: Beat Likely, but Upside Hinges on Drug Updates and US Pricing Policy

Pfizer is set to report Q4 earnings before the open, with expectations for EPS of $0.57 on about $16.85 billion in revenue, continuing its streak of beating earnings in 15 of the last 16 quarters. Yet upside looks limited given 2026 guidance, so focus may shift to new drug data (VESPER-3 obesity study, Lyme vaccine, prostate cancer treatment, NSCLC therapy) and potential US pricing pressure from Medicare negotiations starting in 2028. Options imply roughly a 3.6% move post-earnings, and Wall Street holds a Moderate Buy with a around $28.5 average target (AI target about $29).

Dividend Stocks Set for a 2026 Comeback as Rates Stay Low
business25 days ago

Dividend Stocks Set for a 2026 Comeback as Rates Stay Low

High-quality dividend stocks are expected to rally as government actions likely keep long-term rates suppressed, making cash less attractive. The piece highlights sustainable payers like SCHD, mispriced midstream names such as ONEOK, and value plays like Pfizer and Conagra Brands, noting OKE's 5.6% yield and potential upside if multiples normalize, while warning inflation and sector headwinds require selective stock picking.

Invest $2,670 for $300 Annual Dividend in 2026 with These 3 High-Yield Stocks
finance1 month ago

Invest $2,670 for $300 Annual Dividend in 2026 with These 3 High-Yield Stocks

Investing $2,670 equally among three ultra-high-yield stocks—AGNC Investment, Pfizer, and PennantPark Floating Rate Capital—could generate approximately $300 in super-safe dividend income in 2026, with yields averaging 11.25%. These stocks are selected for their high yields, stability, and growth potential, making them attractive options for income seekers.

Top 3 Discounted Drug Stocks to Watch
business2 months ago

Top 3 Discounted Drug Stocks to Watch

The article discusses the recent developments in the GLP-1 drug market, highlighting Novo Nordisk's new pill and the potential of out-of-favor drug makers like Bristol Myers Squibb, Merck, and Pfizer as long-term investment opportunities due to their efforts to innovate and survive patent cliffs. Despite current setbacks, these companies are positioned for future growth, making them attractive for contrarian investors.